Price
$0.86
Decreased by -2.16%
Dollar Volume
220.59 K
ADR%
5.73
Earnings Report Date (estimate)
Mar 6, 23 (-0.23)
Market Cap.
46.57 M
Shares Float
51.87 M
Shares Outstanding
54.16 M
Beta
2.72
Price / Earnings
-0.49
BPR
99.08
20D Range
0.85 1.03
50D Range
0.76 1.03
200D Range
0.62 2.17
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 2, 22 -0.23
Increased by +39.47%
-0.31
Increased by +25.81%
Nov 1, 22 -0.23
Increased by +37.84%
-0.31
Increased by +25.81%
Aug 2, 22 -0.36
Decreased by -9.09%
-0.36
May 3, 22 -0.32
Increased by +21.95%
-0.41
Increased by +21.95%
Mar 8, 22 -0.38
Increased by +36.67%
-0.47
Increased by +19.15%
Nov 2, 21 -0.37
Increased by +24.49%
-0.45
Increased by +17.78%
Aug 3, 21 -0.33
Decreased by -371.43%
-0.44
Increased by +25.00%
May 3, 21 -0.41
Decreased by -485.71%
-0.43
Increased by +4.65%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 11.46 M
Decreased by -13.73%
-12.54 M
Increased by +13.87%
Decreased by -109.36%
Increased by +0.17%
Jun 30, 22 13.27 M
Decreased by -13.55%
-16.30 M
Decreased by -31.82%
Decreased by -122.89%
Decreased by -52.49%
Mar 31, 22 12.27 M
Increased by +10.32%
-13.22 M
Increased by +9.90%
Decreased by -107.74%
Increased by +18.33%
Dec 31, 21 11.08 M
Increased by +54.96%
-28.95 M
Decreased by -42.11%
Decreased by -261.28%
Increased by +8.29%
Sep 30, 21 13.29 M
Increased by +60.86%
-14.55 M
Increased by +12.06%
Decreased by -109.54%
Increased by +45.33%
Jun 30, 21 15.35 M
Decreased by -29.20%
-12.37 M
Decreased by -429.86%
Decreased by -80.59%
Decreased by -648.44%
Mar 31, 21 11.12 M
Increased by +26.89%
-14.67 M
Increased by +11.24%
Decreased by -131.92%
Increased by +30.05%
Dec 31, 20 7.15 M
Decreased by -56.46%
-20.37 M
Decreased by -61.19%
Decreased by -284.91%
Decreased by -270.20%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.